Pfizer breast cancer drug gets breakthrough label

by The Associated Press

Pfizer Inc. says its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration.

Pfizer shares jumped nearly 3 percent following the news.

The breakthrough designation is meant to speed up development and review of experimental treatments seen as big advances.

The drug, palbociclib (pal-boh-SEYE'-clib), is being evaluated as an initial treatment for a subgroup that includes about 60 percent of postmenopausal women whose breast cancer is locally advanced or has spread elsewhere in the body. Their tumors are fueled by the .

Pfizer is currently running a late-stage study of palbociclib, comparing its effects in combination with letrozole with the effects of letrozole alone. Letrozole, sold under the brand Femara, blocks production of estrogen.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Afinitor approved for advanced breast cancer

Jul 23, 2012

(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food ...

New drug regimens may slow advanced breast cancer

Dec 05, 2012

(HealthDay)—An experimental cancer drug may delay the progression of some advanced breast cancers, while a double dose of an existing cancer drug could help women live longer, according to separate studies ...

Recommended for you

The fine line between breast cancer and normal tissues

6 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

7 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

9 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

New rules for anticancer vaccines

11 hours ago

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in The Journal of Experimental Medicine.

User comments